https://www.selleckchem.com/ph....armacological_epigen
Fluorescent molecular-guided surgery (FGS) is at a tipping point in terms of clinical approval and adoption in a number cancer applications, with ongoing phase 0 and phase 1 clinical trials being carried out in a wide range of cancers using a wide range of agents. The pharmacokinetics of each of these agents and the physiology of these cancers can differ vastly on a patient-to-patient basis, bringing to question how can one fairly compare different methodologies (defined as the combination of imaging agent, system, and protoc
Like
Comment
Share
